SciClone Pharmaceuticals Performance
The entity has a beta of 0.0, which indicates not very significant fluctuations relative to the market. the returns on MARKET and SciClone Pharmaceuticals are completely uncorrelated.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days SciClone Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy essential indicators, SciClone Pharmaceuticals is not utilizing all of its potentials. The recent stock price disarray, may contribute to short-term losses for the investors. ...more
| Target High Price | 14.00 | |
| Target Low Price | 14.00 |
SciClone |
SciClone Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest (100.00) in SciClone Pharmaceuticals on January 19, 2024 and sell it today you would earn a total of 100.00 from holding SciClone Pharmaceuticals or generate -100.0% return on investment over 90 days. SciClone Pharmaceuticals is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than SciClone, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
SciClone Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for SciClone Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as SciClone Pharmaceuticals, and traders can use it to determine the average amount a SciClone Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| SCLN |
Based on monthly moving average SciClone Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of SciClone Pharmaceuticals by adding SciClone Pharmaceuticals to a well-diversified portfolio.
SciClone Pharmaceuticals Fundamentals Growth
SciClone Stock prices reflect investors' perceptions of the future prospects and financial health of SciClone Pharmaceuticals, and SciClone Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on SciClone Stock performance.
| Return On Equity | 0.19 | |||
| Return On Asset | 0.16 | |||
| Profit Margin | 0.21 % | |||
| Operating Margin | 25.82 % | |||
| Current Valuation | 422 M | |||
| Shares Outstanding | 52.19 M | |||
| Price To Earning | 13.75 X | |||
| Price To Book | 2.33 X | |||
| Price To Sales | 3.38 X | |||
| Revenue | 172.02 M | |||
| EBITDA | 45.42 M | |||
| Cash And Equivalents | 157.33 M | |||
| Cash Per Share | 3.01 X | |||
| Total Debt | 2.73 M | |||
| Debt To Equity | 0.01 % | |||
| Book Value Per Share | 3.53 X | |||
| Cash Flow From Operations | 35.74 M | |||
| Earnings Per Share | 0.81 X | |||
| Total Asset | 216.62 M | |||
| Retained Earnings | (115.06 M) | |||
| Current Asset | 168.52 M | |||
| Current Liabilities | 36.82 M |
Things to note about SciClone Pharmaceuticals performance evaluation
Checking the ongoing alerts about SciClone Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for SciClone Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| SciClone Pharmaceuticals is not yet fully synchronised with the market data | |
| SciClone Pharmaceuticals has some characteristics of a very speculative penny stock | |
| SciClone Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Over 80.0% of the company shares are owned by institutional investors |
- Analyzing SciClone Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether SciClone Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining SciClone Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating SciClone Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of SciClone Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of SciClone Pharmaceuticals' stock. These opinions can provide insight into SciClone Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Other Consideration for investing in SciClone Stock
If you are still planning to invest in SciClone Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the SciClone Pharmaceuticals' history and understand the potential risks before investing.
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences |